Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Increases By 218.4%

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 182,364 shares, a growth of 218.4% from the July 30th total of 57,276 shares. Approximately 5.3% of the shares of the company are sold short. Based on an average daily volume of 200,659 shares, the short-interest ratio is presently 0.9 days.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently bought and sold shares of GOVX. Ieq Capital LLC bought a new stake in GeoVax Labs during the 2nd quarter worth approximately $1,352,000. NFJ Investment Group LLC purchased a new position in shares of GeoVax Labs during the 2nd quarter valued at $1,419,000. Rice Hall James & Associates LLC bought a new position in shares of GeoVax Labs in the second quarter worth $1,888,000. Man Group plc purchased a new stake in shares of GeoVax Labs in the second quarter worth $2,396,000. Finally, Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the first quarter worth $27,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on GOVX. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GeoVax Labs has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Trading Up 0.6%

Shares of NASDAQ GOVX traded up $0.00 during mid-day trading on Friday, hitting $0.72. The company had a trading volume of 685,952 shares, compared to its average volume of 2,152,721. GeoVax Labs has a 1 year low of $0.59 and a 1 year high of $19.20. The company has a market capitalization of $2.50 million, a price-to-earnings ratio of -0.06 and a beta of 3.73. The stock’s 50-day moving average price is $0.93 and its 200-day moving average price is $1.39.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19. As a group, equities research analysts forecast that GeoVax Labs will post -4.94 earnings per share for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.